Extracorporeal elimination in acute valproic acid poisoning
- PMID: 19656009
- DOI: 10.1080/15563650903167772
Extracorporeal elimination in acute valproic acid poisoning
Abstract
Introduction: Valproic acid (VPA) is an antiepileptic drug that is now used for a variety of neurological and psychiatric indications. Clinical manifestations of severe VPA poisoning include central nervous system depression, hypotension, electrolyte and acid-base disturbances, and hyperammonemia. Although extracorporeal methods have been used to enhance VPA elimination, the indications for and effectiveness of these methods have not been fully characterized.
Methods: A systematic literature search was performed, which identified 31 reports of the use of extracorporeal elimination in VPA poisoning.
Results: VPA has a low molecular weight of 144 Da and a low volume of distribution, but at therapeutic concentrations, it is highly protein bound (85-95%). Protein-binding studies during hemodialysis demonstrate that at high VPA concentrations protein binding is saturated, allowing substantial clearance of the free VPA fraction. Case reports consistently show that during hemodialysis the elimination half-life of VPA can be reduced to around 2 h and the enhanced VPA clearance is often associated with improvement clinically. Hemoperfusion also enhances VPA elimination, but its effectiveness may be limited by column saturation. "In-series" hemodialysis and hemoperfusion have been used, but the combination offers little benefit over hemodialysis alone. Continuous renal replacement techniques are increasingly being used although continuous venovenous hemofiltration and continuous venovenous hemodiafiltration do not appear to be as effective as hemodialysis. No controlled trials are available comparing clinical outcomes with or without extracorporeal elimination in VPA poisoning. Novel techniques such as slow low-efficiency dialysis with filtration and supplementation of the dialysate with albumin are being evaluated.
Indications: Extracorporeal methods of elimination should be considered in patients with features of severe VPA poisoning (coma or hemodynamic compromise) and plasma VPA concentration >850 mg/L (coma is more likely to be present at concentrations >850 mg/L), particularly if severe hyperammonemia and electrolyte and acid-base disturbances are present.
Conclusions: Based on limited anecdotal evidence, hemodialysis appears to be the extracorporeal method of choice to enhance VPA elimination in acute poisoning. Controlled, randomized trials are required to better characterize the effect of extracorporeal treatment on clinical outcome.
Similar articles
-
Severe valproic acid intoxication: case study on the unbound fraction and the applicability of extracorporeal elimination.Eur J Emerg Med. 2009 Dec;16(6):330-2. doi: 10.1097/MEJ.0b013e32832c7b18. Eur J Emerg Med. 2009. PMID: 19424075
-
Extracorporeal management of valproic acid toxicity: a case report and review of the literature.Semin Dial. 2005 Jan-Feb;18(1):62-6. doi: 10.1111/j.1525-139X.2005.18106.x. Semin Dial. 2005. PMID: 15663767 Review.
-
Extracorporeal removal of toxic valproic acid levels in children.Pediatr Nephrol. 2002 May;17(5):312-5. doi: 10.1007/s00467-002-0841-2. Pediatr Nephrol. 2002. PMID: 12042885
-
Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup.Clin Toxicol (Phila). 2015 Jun;53(5):454-65. doi: 10.3109/15563650.2015.1035441. Clin Toxicol (Phila). 2015. PMID: 25950372
-
Enhanced clearance of highly protein-bound drugs by albumin-supplemented dialysate during modeled continuous hemodialysis.Nephrol Dial Transplant. 2009 Jan;24(1):231-8. doi: 10.1093/ndt/gfn467. Epub 2008 Aug 22. Nephrol Dial Transplant. 2009. PMID: 18723569
Cited by
-
Management of toxic ingestions with the use of renal replacement therapy.Pediatr Nephrol. 2011 Apr;26(4):535-41. doi: 10.1007/s00467-010-1654-3. Epub 2010 Oct 12. Pediatr Nephrol. 2011. PMID: 20938691 Free PMC article. Review.
-
Targeting prolyl endopeptidase with valproic acid as a potential modulator of neutrophilic inflammation.PLoS One. 2014 May 16;9(5):e97594. doi: 10.1371/journal.pone.0097594. eCollection 2014. PLoS One. 2014. PMID: 24835793 Free PMC article.
-
Valproic acid determination by liquid chromatography coupled to mass spectrometry (LC-MS/MS) in whole blood for forensic purposes.Drug Test Anal. 2023 Jan;15(1):128-133. doi: 10.1002/dta.3362. Epub 2022 Sep 2. Drug Test Anal. 2023. PMID: 36028251 Free PMC article.
-
Renal replacement therapy in the management of intoxications in children: recommendations from the Pediatric Continuous Renal Replacement Therapy (PCRRT) workgroup.Pediatr Nephrol. 2019 Nov;34(11):2427-2448. doi: 10.1007/s00467-019-04319-2. Epub 2019 Aug 24. Pediatr Nephrol. 2019. PMID: 31446483
-
In vitro Assessment of Drug Adsorption Profiles during Hemoadsorption Therapy.Blood Purif. 2025;54(4-5):218-225. doi: 10.1159/000545120. Epub 2025 Mar 20. Blood Purif. 2025. PMID: 40112784 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical